Shiyao Holding Group Co., Ltd. was established in 1997 with a registered capital of 52.136 million yuan. In 2022, its sales revenue was 45.2 billion yuan, and its R&D investment was 3.987 billion yuan. It has developed into an international innovative enterprise with 28000 employees, ranking 25th among the world's top 1000 pharmaceutical companies.
Shijiazhuang Pharma Group has built national science and technology platforms such as the State Key Laboratory for New Pharmaceutical Preparations and Excipients, the National Enterprise Technology Center, and the National Local Joint Engineering Laboratory. It has built an integrated research and development system at home and abroad, a high-end research and development team of more than 2000 people, research and development centers in Shijiazhuang, Beijing, Shanghai, and other places, and four overseas research and development centers in California, Texas, New Jersey, and other places in the United States. Relying on eight major technological platforms such as nanomedicine, mRNA, and ADC, there are over 110 new drug projects under research, including over 40 large molecules, over 40 small molecules, and over 30 new formulations. We have 825 authorized invention patents.
Project introduction: 
breast cancer has become the malignant tumor with the highest incidence rate among women, and about 2.1 million new cases are added every year in the world. About 75% of breast cancer are estrogen receptor (ER) positive with HER2 negative (ER+/HER2-). In postmenopausal, locally advanced or metastatic breast cancer patients, endocrine therapy is still the means of systematic treatment. Endocrine therapy drugs are mainly targeted at the synthesis of peripheral estrogen or ER itself, including Aromatase inhibitors (AI; letrozole, anastrozole, and Exemestane), selective estrogen receptor modulators (SERM; tamoxifen), and selective estrogen receptor degradation agents (SERD; fluvastatin). 
Intended countries: The
main issues to be solved through the project are not limited to: 
global SERD products have been approved for injection with Fluvastatin, but the convenience of use needs to be improved. The only approved oral SERD Elastron has been approved in the United States, but it has not yet been listed in China. The development of an oral SERD is of great significance for the benefit of the life and quality of life of breast cancer patients.